Global Nucleic Acid Based Gene Therapy Market Data 2024, Forecast To 2033
17 Jan, 2024
The nucleic acid-based gene therapy market has witnessed robust growth, escalating from $0.75 billion in 2023 to $0.82 billion in 2024, demonstrating a noteworthy 9.6% CAGR. Historical growth is credited to an increased understanding of human genetics, rising demand for personalized medicine, expanding pipelines of gene therapy products, and growing governmental support for genetic disorder and cancer therapy. Future growth is projected, estimating a market size of $1.2 billion in 2028, driven by expanding indications, increased funding, patient advocacy, and a broader scope of gene therapy applications. Key trends include ex vivo gene editing, advances in in vivo gene editing, combination therapies, targeted delivery systems, and a focus on rare diseases.
Global Nucleic Acid Based Gene Therapy Market Key Driver
Increased government and corporate support drive demand for nucleic acid-based gene therapy. Nucleic acid therapeutics target genetic expression, offering potential cures for diseases like cystic fibrosis and diabetes. Government support, such as the National Institute of Health's $34 million annual investment in HIV treatment research, fosters growth in the nucleic acid-based gene therapy market.
Get A Free Sample Of The Global Nucleic Acid Based Gene Therapy Market ReportGlobal Nucleic Acid Based Gene Therapy Market Segments
The nucleic acid based gene therapy market covered in this report is segmented –
1) By Technology: Anti-Sence and Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers, Other Technologies
2) By Application: Oncology, Muscular Dystrophy/ Muscular Disorders, Rare Diseases
3) By End User: Hospitals And Clinics, Academic And Research Institutes
By Geography: The regions covered in the nucleic acid based gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions
North America was the largest region in the nucleic acid-based gene therapy market in 2023. Western Europe was the second-largest region in the nucleic acid-based gene therapy market report. The regions covered in the nucleic acid based gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
Major Nucleic Acid Based Gene Therapy Industry Players
Celsion Corporation, Wave Life Sciences, Imugene Ltd., Caperna LLC, Phylogica Limited, Protagonist Therapeutics Inc., Benitec Biopharma Ltd., EGEN, BioMedica, Transgene SA, Copernicus Therapeutics Inc., 4D Molecular Therapeutics Inc., Abeona Therapeutics Inc., Alnylam Pharmaceuticals Inc., Amgen Inc., Beam Therapeutics Inc., BioNTech SE, Bluebird Bio Inc., CRISPR Therapeutics AG, Editas Medicine Inc., Genevant Sciences Inc., Homology Medicines Inc., Intellia Therapeutics Inc., Ionis Pharmaceuticals Inc., MaxCyte Inc., Moderna Inc., Novartis International AG, Orchard Therapeutics plc, Precision BioSciences Inc., REGENXBIO Inc.
Get The Full Global Nucleic Acid Based Gene Therapy Market Report
Nucleic Acid Based Gene Therapy Market Overview
Gene therapy is used for correcting defective genes that are responsible for disease development. Nucleic acid-based therapeutics is used to treat genetic disorders and diseases for which there exists no permanent cure, such as anemia, sickle cell, cystic fibrosis, and thalassemia.
Nucleic Acid Based Gene Therapy Global Market Report 2023 provides data on the global nucleic acid based gene therapy market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The nucleic acid based gene therapy market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.